Hong Kong biopharma stocks rebound, Remegen up over 10%, WuXi Bio up over 7%, WuXi AppTec and Junshi Bio both up over 5%

Hong Kong biopharma stocks rebound, Remegen up over 10%, WuXi Bio up over 7%, WuXi AppTec and Junshi Bio both up over 5%

Hong Kong biopharma stocks have rebounded significantly in the wake of recent positive developments. Remegen (REMEGEN) saw a notable 10% increase, while WuXi Bio (WUXI) and WuXi AppTec (WUXI) both experienced a 7% and 5% uptick, respectively. Junshi Bio (JUNSHI) also showed a 5% rise, reflecting a general optimism in the sector.

The rebound can be attributed to several key announcements. WuXi AppTec, a leading provider of R&D and manufacturing services in the pharmaceutical and life science industries, completed its second RMB1.0 billion A-share repurchase program in 2025. This move aimed to enhance shareholder value and protect shareholder interests. The repurchase program, which totaled RMB1.0 billion, represented 0.40% of the company's total share capital as of August 27, 2025 [1].

The company's share repurchases and cash dividends for the year have totaled RMB5.84 billion, which accounts for over 60% of the net profit attributable to the Company's owners in 2024. This significant payout underscores the company's commitment to returning value to shareholders, thereby boosting investor confidence.

The positive sentiment in the sector is also reflected in the performance of other biopharma stocks. Remegen's 10% increase highlights its strong market position and potential for growth. Similarly, WuXi Bio and Junshi Bio's gains indicate investor optimism in their respective business models and market prospects.

Overall, the rebound in Hong Kong biopharma stocks suggests a bullish outlook for the sector, driven by positive corporate actions and investor confidence.

References:
[1] https://www.morningstar.com/news/pr-newswire/20250827cn60216/wuxi-apptec-completes-second-rmb10-billion-a-share-repurchase-program-in-2025-all-repurchased-shares-to-be-cancelled